New Zealand Firms Remain Upbeat Despite Weak Trading Conditions
A net 22% of businesses expect the economy to improve in the next 12 months, NZIER said Tuesday in its quarterly survey of business opinion. That's up from 19% in the first quarter and is the highest since 2016.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
4 hours ago
- Wall Street Journal
Powell Cites Solid Economy in Keeping Wait-and-See Stance on Rates
Federal Reserve Chair Jerome Powell repeated his view that steady economic activity would allow the central bank to wait and see the effects that tariff increases have on prices and economic growth before resuming interest-rate reductions. 'We're simply taking some time,' Powell said Tuesday. 'As long as the U.S. economy is in solid shape, we think the prudent thing to do is wait and learn more and see what those effects might be.'
Yahoo
4 hours ago
- Yahoo
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. 'Securing regulatory approvals in Australia and New Zealand mark another important step in expanding global access to our innovative infertility solutions,' said Kathy Lee-Sepsick, CEO and Founder of Femasys. 'With FemaSeed and FemVue, we are delivering much-needed, first-line options that address critical gaps in care for women struggling with infertility. These milestones not only validate the clinical value of our platform but also create meaningful commercial opportunities as we continue to grow revenue and broaden our global footprint.' About FemaSeed FemaSeed® is a next-generation artificial insemination solution that enhances fertilization by precisely delivering sperm to the fallopian tube, the natural site of conception. Offering a safe, accessible, and cost-effective first-line treatment, FemaSeed provides a more effective alternative to intrauterine insemination (IUI). In the pivotal clinical trial (NCT0468847), it achieved over double the pregnancy rates of IUI in cases of low male sperm count.1 FemaSeed is an affordable, less invasive, lower-risk option before IVF. It is authorized for use in the U.S., Europe, UK, Canada, Israel, Australia and New Zealand. Learn more at About FemVue FemVue® is a transformative, ultrasound-based alternative to radiologic imaging procedures for evaluating fallopian tube patency. It creates natural saline and air contrast for a safe, reliable, real-time assessment, all within the comfort of the gynecologist's office. When combined with a uterine cavity evaluation, it offers a comprehensive fertility exam. Because FemaSeed® requires at least one open fallopian tube, FemVue serves as an essential companion diagnostic to guide appropriate patient selection. It is authorized for use in the U.S., Japan, Europe, UK, Canada, Israel, Australia and New Zealand. Learn more at About FemasysFemasys is a leading biomedical innovator focused on addressing critical unmet needs in women's health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys' fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data show FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1 FemBloc® permanent birth control, the first and only non-surgical, in-office alternative to centuries-old surgical sterilization, has received regulatory approval in Europe. Commercialization of this highly cost effective, convenient and significantly safer approach will begin in Spain through engaged partnerships followed by select European countries. Alongside FemBloc, the FemChec® is a diagnostic product that enables an ultrasound-based test to confirm procedure success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is ongoing. Learn more at or follow us on X, Facebook and LinkedIn. References1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08. 2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05. Forward-Looking Statements This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'pending,' 'intend,' 'believe,' 'suggests,' 'potential,' 'hope,' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors: IR@ Media Contact: Media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Delegat Group names Murray Annabell permanent CEO
Delegat Group has formally appointed Murray Annabell as its new chief executive officer, effective from today (1 July). He was made acting CEO earlier this year, following the departure of managing director Steve Carden at the end January. Annabell has been with the New Zealand-based winemaker for over 20 years, including the last 13 years as chief financial officer, according to a New Zealand stock exchange filing. According to the Oyster Bay brand owner, he has had "a pivotal role in shaping Delegat's financial strategy and supporting our senior leadership team". In a statement, the company's chair Jim Delegat said 'after an external search, we are thrilled Murray has accepted the Chief Executive Officer position. "Murray's extensive knowledge of our business and the global wine industry, combined with his proven leadership, are critical to the company's continued success at this important time.' Riki Maden, currently group financial controller, will take the position of acting chief financial officer whilst Delegat looks for a replacement. In April, the Barossa Valley Estate maker lowered its profit forecast for 2025, blaming the impact of US tariffs on sales. In a New Zealand stock exchange filing at the time, the company said the US move to place a 10% tariff on all imports into the country had led to 'significant uncertainty expressed by our US distributors regarding forward shipments for Q4 (April – June 2025)'. 'This uncertainty has led to a revised global case sales and profit guidance,' it said. Delegat cut its projection on operating net profit after tax to $47-50m for the FY25 year, down from the previous forecast of $55-60m. Delegat's financial year ends on 30 June. It is also projecting global case sales of 3,182,000 for the year, a 5% fall from prior estimates and 12% lower than previous year's sales. "Delegat Group names Murray Annabell permanent CEO" was originally created and published by Just Drinks, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
